130 related articles for article (PubMed ID: 8388920)
1. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.
Miller AA; Tolley EA; Niell HB; Griffin JP; Mauer AM
J Clin Oncol; 1993 Jun; 11(6):1179-88. PubMed ID: 8388920
[TBL] [Abstract][Full Text] [Related]
2. Predictive performance of a pharmacodynamic model for oral etoposide.
Miller AA; Tolley EA
Cancer Res; 1994 Apr; 54(8):2080-3. PubMed ID: 8174108
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.
Miller AA; Tolley EA; Niell HB; Stewart CF; Griffin JP
Cancer Chemother Pharmacol; 1992; 31(2):161-6. PubMed ID: 1333371
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer.
Miller AA; Niell HB; Griffin JP
Lung Cancer; 1995 Mar; 12(1-2):59-65. PubMed ID: 7600031
[TBL] [Abstract][Full Text] [Related]
8. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
[TBL] [Abstract][Full Text] [Related]
9. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
10. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
Minami H; Ando Y; Sakai S; Shimokata K
J Clin Oncol; 1995 Jan; 13(1):191-9. PubMed ID: 7799020
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report.
Shepherd FA; Goss PE; Latreille J; Stewart D; Logan D; Evans WK; Maroun J; Warner E
Semin Oncol; 1990 Apr; 17(2 Suppl 4):19-23. PubMed ID: 2159185
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
Minami H; Shimokata K; Saka H; Saito H; Ando Y; Senda K; Nomura F; Sakai S
J Clin Oncol; 1993 Aug; 11(8):1602-8. PubMed ID: 8336196
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
17. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
Mehdi SA; Perry MC; Herndon JE; Crawford J; Young R; Graziano SL
J Interferon Cytokine Res; 1998 Aug; 18(8):623-7. PubMed ID: 9726444
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
[TBL] [Abstract][Full Text] [Related]
19. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
